Release Summary

Seres Therapeutics Inc., (NASDAQ:MCRB), today announced plans to initiate a new SER-109 Phase 2 clinical study (ECOSPOR III) in patients with multiply recurrent Clostridium difficile infection.

Seres Therapeutics Inc.